JP2023507848A5 - - Google Patents

Info

Publication number
JP2023507848A5
JP2023507848A5 JP2022538737A JP2022538737A JP2023507848A5 JP 2023507848 A5 JP2023507848 A5 JP 2023507848A5 JP 2022538737 A JP2022538737 A JP 2022538737A JP 2022538737 A JP2022538737 A JP 2022538737A JP 2023507848 A5 JP2023507848 A5 JP 2023507848A5
Authority
JP
Japan
Prior art keywords
cancer
composition according
lag
cdr
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022538737A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023507848A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/065873 external-priority patent/WO2021133653A1/en
Publication of JP2023507848A publication Critical patent/JP2023507848A/ja
Publication of JP2023507848A5 publication Critical patent/JP2023507848A5/ja
Priority to JP2025154757A priority Critical patent/JP2026001028A/ja
Pending legal-status Critical Current

Links

JP2022538737A 2019-12-23 2020-12-18 癌の治療のための療法 Pending JP2023507848A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025154757A JP2026001028A (ja) 2019-12-23 2025-09-18 癌の治療のための療法

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201962952878P 2019-12-23 2019-12-23
US201962952859P 2019-12-23 2019-12-23
US62/952,878 2019-12-23
US62/952,859 2019-12-23
US202063019857P 2020-05-04 2020-05-04
US63/019,857 2020-05-04
US202063021556P 2020-05-07 2020-05-07
US63/021,556 2020-05-07
US202063031453P 2020-05-28 2020-05-28
US63/031,453 2020-05-28
US202063123581P 2020-12-10 2020-12-10
US63/123,581 2020-12-10
PCT/US2020/065873 WO2021133653A1 (en) 2019-12-23 2020-12-18 Therapy for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025154757A Division JP2026001028A (ja) 2019-12-23 2025-09-18 癌の治療のための療法

Publications (2)

Publication Number Publication Date
JP2023507848A JP2023507848A (ja) 2023-02-27
JP2023507848A5 true JP2023507848A5 (cg-RX-API-DMAC7.html) 2023-12-21

Family

ID=76575359

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022538737A Pending JP2023507848A (ja) 2019-12-23 2020-12-18 癌の治療のための療法
JP2025154757A Pending JP2026001028A (ja) 2019-12-23 2025-09-18 癌の治療のための療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025154757A Pending JP2026001028A (ja) 2019-12-23 2025-09-18 癌の治療のための療法

Country Status (13)

Country Link
US (1) US20230056230A1 (cg-RX-API-DMAC7.html)
EP (1) EP4081248A4 (cg-RX-API-DMAC7.html)
JP (2) JP2023507848A (cg-RX-API-DMAC7.html)
KR (1) KR20220119694A (cg-RX-API-DMAC7.html)
CN (1) CN114901306A (cg-RX-API-DMAC7.html)
AU (1) AU2020412595A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022012437A2 (cg-RX-API-DMAC7.html)
CA (1) CA3165839A1 (cg-RX-API-DMAC7.html)
IL (1) IL294207A (cg-RX-API-DMAC7.html)
MX (1) MX2022007790A (cg-RX-API-DMAC7.html)
TW (1) TW202138387A (cg-RX-API-DMAC7.html)
WO (1) WO2021133653A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202206743B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7745556B2 (ja) * 2020-02-21 2025-09-29 マクロジェニクス,インコーポレーテッド Cd137結合分子及びその使用
CA3196496A1 (en) * 2020-10-23 2022-04-28 Laurence David TOMS Lag-3 antagonist therapy for lung cancer
KR20240028452A (ko) * 2021-07-02 2024-03-05 제넨테크, 인크. 암을 치료하기 위한 방법 및 조성물
KR20240038005A (ko) * 2021-07-16 2024-03-22 마크로제닉스, 인크. B7-h3 항체의 약학적 조성물 및 그것의 용도
IL309120A (en) * 2021-07-28 2024-02-01 Hoffmann La Roche Methods and compositions for the treatment of cancer
EP4410835A4 (en) * 2021-09-29 2025-09-24 Akeso Biopharma Inc ANTI-LAG3 ANTIBODY, PHARMACEUTICAL COMPOSITION AND USE
TW202328198A (zh) * 2021-10-21 2023-07-16 大陸商杭州阿諾生物醫藥科技有限公司 一種融合多肽及其用途
US20240117051A1 (en) * 2022-09-09 2024-04-11 Akeso Biopharma, Inc. Therapeutic combination and use thereof
TW202436339A (zh) * 2023-01-31 2024-09-16 瑞士商赫孚孟拉羅股份公司 治療選自非小細胞肺癌或三陰性乳癌的癌症之用途
WO2024163009A1 (en) * 2023-01-31 2024-08-08 Genentech, Inc. Methods and compositions for treating urothelial bladder cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2542256T3 (da) * 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
RS64268B1 (sr) * 2013-09-20 2023-07-31 Bristol Myers Squibb Co Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora
TWI693232B (zh) * 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
TWI773646B (zh) * 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
PE20231958A1 (es) * 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
JP2018523686A (ja) * 2015-08-17 2018-08-23 マクロジェニクス,インコーポレーテッド B7‐h3及びcd3に結合できる二重特異性1価ダイアボディ並びにその使用
CN108367069B (zh) * 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
CN109069633A (zh) * 2016-04-15 2018-12-21 宏观基因有限公司 新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法
MX2018014950A (es) * 2016-06-07 2019-04-25 Macrogenics Inc Terapia de combinacion.
JP7085709B2 (ja) * 2016-06-20 2022-06-17 エフ-スター セラピューティクス リミテッド Pd-l1及びlag-3に結合する結合分子
US20200148785A1 (en) * 2017-03-29 2020-05-14 Glycotope (GmbH) Pd-l1 and ta-muc1 antibodies
CA3052532A1 (en) * 2017-04-05 2018-10-11 F. Hoffmann-La Roche Ag Bispecific antibodies specifically binding to pd1 and lag3
JP7301002B2 (ja) * 2017-05-30 2023-06-30 ブリストル-マイヤーズ スクイブ カンパニー 抗lag-3抗体または抗lag-3抗体および抗pd-1もしくは抗pd-l1抗体を含む組成物
WO2019148412A1 (en) * 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
US20210115138A1 (en) * 2018-03-20 2021-04-22 WuXi Biologics Ireland Limited Novel bispecific pd-1/lag-3 antibody molecules

Similar Documents

Publication Publication Date Title
Reichert et al. The future of antibodies as cancer drugs
JP6953612B2 (ja) チェックポイントインヒビター二重特異性抗体
JP7720785B2 (ja) 低pHで結合するために特異性が増強されたイピリムマブバリアント
Shim One target, different effects: a comparison of distinct therapeutic antibodies against the same targets
JP2023519254A5 (cg-RX-API-DMAC7.html)
JP2020501531A5 (cg-RX-API-DMAC7.html)
JP2009541492A5 (cg-RX-API-DMAC7.html)
Hinoda et al. Monoclonal antibodies as effective therapeutic agents for solid tumors
JP2013529059A5 (cg-RX-API-DMAC7.html)
HRP20241289T1 (hr) Molekule za vezanje pd-1 i postupci za njihovu uporabu
JP2021525544A5 (cg-RX-API-DMAC7.html)
JP2021510736A5 (cg-RX-API-DMAC7.html)
CA2872226A1 (en) Humanized pan-her antibody compositions
CN114901306A (zh) 用于治疗癌症的疗法
EP4588524A2 (en) Anti-tigit and anti-pvrig in monotherapy and combination treatments
JP2023536086A5 (cg-RX-API-DMAC7.html)
US20250215087A1 (en) Combination therapy of kras inhibitor and treg depleting agent
EP3929213A1 (en) Anti-pd-l1 antibody and use thereof
CN110997000A (zh) 用于治疗ErbB-2/ErbB-3阳性肿瘤的抗体
MX2015000730A (es) Tratamientos terapeuticos novedosos con anticuerpos anti-her2 que tienen una fucosilacion baja.
JP2023548375A (ja) Erbb3変異陽性がんを有する対象を治療するための手段及び方法
WO2021058735A1 (en) Cancer treatment with anti-met antibody compositions
KR20250130296A (ko) 항-ccr8 항체 및 이의 용도
JP7726978B2 (ja) 抗cldn-18.2抗体及びその用途
Zhu et al. Next generation of antibody therapy for cancer